NeoGenomics Reports $7.5 Million Loss for Third Quarter

The diagnostics company reported a 6-cent-per-share loss, impacting how operators evaluate fiscal stability in the sector.

Updated on Oct. 28, 2026 in Corporate Finance

Bold flat-color editorial illustration of a single diagnostic vial, conveying the clinical precision of the medical diagnostics sector. — NeoGenomics reported a $7.5 million net loss for the third quarter of 2026, as accounting charges impacted overall bottom-line profitability. AI Illustration. Upload story photo >

Live Poll

Does a company beating earnings estimates make you more confident in the current stock market?

Fort Myers-based NeoGenomics reported a net loss of $7.5 million for the third quarter of 2026. While the company recorded $209.3 million in revenue, shareholders saw a loss of 6 cents per share for the period.

Why it matters

Operators monitor these figures to gauge the company's fiscal stability and its ability to scale operations in the competitive diagnostic testing market. The difference between net loss and adjusted earnings illustrates the impact of accounting expenses like stock options on the bottom line.

NeoGenomics reported a $7.5 million net loss during the third quarter of 2026, alongside $209.3 million in revenue. The company recorded a loss of 6 cents per share, though adjusted earnings reached 7 cents per share for the period.

The players

NeoGenomics

A Fort Myers-based oncology testing and diagnostics firm providing genetic and molecular services to hospitals and private practices.

The details

The results reflect adjustments for stock option expenses and amortization costs, which shifted the net loss figure toward an adjusted earnings per share of 7 cents. This highlights how non-cash accounting charges can create a divide between operational performance and bottom-line profit reported to stakeholders.

Q3 2026: The reported period for the company's financial results.

Market Landscape

NeoGenomics' reporting follows the Financial Accounting Standards Board's rules for stock-based compensation and amortization. This reconciliation process is standard for firms managing high non-cash expenses while scaling diagnostic operations.

Operators should note how the firm isolates non-cash expenses to project year-end profitability. Reviewing these adjusted metrics is a standard step when benchmarking similar firms in the high-overhead diagnostic sector.

The takeaway

Understanding the spread between net loss and adjusted earnings is vital for evaluating firm health in capital-intensive industries. Operators should monitor the company's stated path to full-year earnings of 21 to 22 cents per share as a key signal for the upcoming fiscal cycle.